SuperGen, Inc. To Present At Jefferies Life Sciences Conference

DUBLIN, Calif., June 21 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the Jefferies Life Sciences Conference, being held at the Mandarin Oriental in New York City on Wednesday, June 28, 2006 at 1:15 p.m. EDT. Dr. Manuso will provide a brief corporate overview and discuss the Company's recent progress.

A live webcast of Dr. Manuso's presentation will be available on the Investor Relations section of the Company's website at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com.

Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications Director of Investor Relations & Business Development Tel: (212) 845-4271 Tel: (925) 560-0100 x111 E-mail: E-mail: tenns@supergen.comsharon.weinstein@eurorscg.com

SuperGen, Inc.

CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & BusinessDevelopment of SuperGen, Inc., +1-925-560-0100, ext. 111,tenns@supergen.com; or Sharon Weinstein, Director of Investor Relations ofNoonan Russo, +1-212-845-4271, sharon.weinstein@eurorscg.com, for SuperGen,Inc.

Back to news